One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2021-149333
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 5 |
Affiliation: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Northwestern University, Morristown Medical Center, University Hospitals of Cleveland, Sylvester Comprehensive Cancer Center, Aptose Biosciences (United States), University of California, San DiegoA Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
